ODAIA Raises Series C to Scale Commercial Intelligence for Pharma

TORONTO — Nov 12, 2026
ODAIA, an AI company delivering predictive commercial intelligence for pharma, today announced it has closed a US$15 million Series C financing led by Monograph Capital and anchored by strategic investor PHM, the leading health media agency in the U.S., part of Publicis Groupe.
Investors from ODAIA’s earlier rounds are also returning: BDC Capital, Flint Capital, Innospark Ventures, and Graphite Ventures from its Series A and Threshold Ventures and Wittington Ventures from its Series B. ODAIA will use the capital to grow within the enterprise pharma accounts it already serves and continue innovating its commercial intelligence platform.
Leading biopharmaceutical companies use ODAIA for commercial intelligence and workflow automations for field and marketing teams across many therapeutic areas. ODAIA predicts patient journeys, uncovers missed Rx opportunities, determines which healthcare professionals(HCPs) to prioritize through which channels, and keeps sales and marketing working from one brand strategy.
“Pharma has proven that AI works in commercial. The hard part now is scaling it. Most companies can show results on one brand, and every new brand or therapeutic area still costs another team and another build. ODAIA started by helping field teams decide where to focus. Today our platform is the commercial intelligence infrastructure that scales what’s working across brand, marketing, and field teams, and across a company’s whole portfolio. This round lets us go deeper with the enterprise customers we already serve and, with PHM, bring that infrastructure to more of the industry, faster."
- Philip Poulidis, CEO & CoFounder, ODAIA
“We have watched the ODAIA team turn predictive AI into decisions that pharma brand and field teams act on every day. The ODAIA team has a track record of helping large and specialty pharma brands reach the physicians whose patients need their therapies most.”
- Charles Conn, Co-Founder & Partner, Monograph Capital
One strategy for brand, field, and marketing
Inside most pharma companies, data sits in many systems owned by separate teams, so brand, marketing, and field each work from a different picture of the same physician. Patients get missed, field and digital effort lands in the wrong places, and nobody can say with confidence what is influencing HCP decisions. ODAIA’s commercial intelligence platform provides the foundation underneath. It brings disparate data, field sales activity, and digital engagement into one view of each HCP that brand, marketing, and field teams all work from.
Brand teams codify their strategy once in Brand Strategy Studio, and ODAIA’s decision engines turn it into HCP-level choices about who to reach, through which channel, when, and with what message. Extending to a new brand or therapeutic area is a matter of configuration. The platform identifies physicians whose patients are likely to need a therapy, often months before a diagnosis shows up in the data. Field Intelligence delivers prioritized call plans to field teams inside their CRM, and Marketing Intelligence orchestrates individualized HCP journeys across digital and partner channels.
Every ODAIA recommendation comes with the reasoning behind it, so commercial and compliance teams can see why. Commercial leaders ask questions of their data in plain language and get finished analysis in minutes. The platform continuously measures engagement and prescription lift and feeds the results into the next decision, so teams can adjust as markets change.
Alongside the financing, ODAIA signed a commercial Platform Agreement that makes PHM, Publicis Groupe’s U.S. health media agency, ODAIA’s exclusive agency partner in the U.S.
ODAIA continues to work directly with pharma companies, and its platform works alongside the CRM, in-house analytics models, and data infrastructure each brand already uses. The partnership connects signals across digital media and field sales so clients can coordinate HCP engagement across both.




